Session Time: 4:30pm-6:00pm
Presentation Time: 5:06pm-5:18pm
Direct-acting antivirals (DAAs) have been shown to have high cure rates in hepatitis C (HCV)-positive liver transplantation (LT) recipients. The organ donor shortage has led to the use of HCV-positive allografts in HCV-positive recipients, as well as possible use in HCV-negative recipients. The aim of this study is to determine current attitudes of transplant programs towards the use of HCV-positive allografts.
This was a descriptive, cross-sectional study utilizing a web based-survey sent to all liver transplant programs in the United States.
We polled 117 transplant centers and received 46 responses. One incomplete response was excluded from analysis.
Respondents were 82% male and 18% female, and were comprised of 61% physicians and 39% surgeons. All UNOS regions were represented, except for regions 4 and 6. The majority of programs had transplanted more than 51 livers per year, with HCV being the leading indication. Overall, 83% of respondents had a formal program policy on the use of HCV-positive allografts, and 96% of respondents have already used them. Of these 44 respondents, 7 programs would consider using an HCV-positive allograft in an HCV-negative candidate, and 7 have intentionally done so.
Currently 98% of respondents treat HCV-positive LT recipients with DAAs. Respondents were more likely to consider use of HCV-positive allografts in HCV-negative recipients in situations where recipients had a higher degree of illness severity (table 1). The most important nullifying factors in using an HCV-positive allograft in an HCV-negative recipient identified by transplant program directors were related to recipient concerns and concern about severe early recurrent hepatitis.
Table 1. Willingness of programs to use an HCV+ allograft in an HCV-candidate, by listing status.
|HCC not meeting criteria for exception points|
Though many programs have a formal policy on the use of HCV-positive allografts, and several have used them in HCV-positive recipients, use of HCV-positive allografts in HCV-negative recipients is not yet widespread.
CITATION INFORMATION: Kilaru S, Tapper E, Curry M. Assessment of Attitudes Toward Use of Hepatitis C Positive Liver Allografts in US Transplant Centers. Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:Kilaru S, Tapper E, Curry M. Assessment of Attitudes Toward Use of Hepatitis C Positive Liver Allografts in US Transplant Centers. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/assessment-of-attitudes-toward-use-of-hepatitis-c-positive-liver-allografts-in-us-transplant-centers/. Accessed June 6, 2020.
« Back to 2017 American Transplant Congress